Stavudine:pharmacology,clinical use and future role
- 23 February 1997
- journal article
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 6 (2) , 191-200
- https://doi.org/10.1517/13543784.6.2.191
Abstract
Stavudine is a nucleoside analogue reverse transcriptase inhibitor of HIV-1 and HIV-2 and demonstrates in vitro activity with an acceptable therapeutic index in a range of T-lymphocyte and haematopoietic precursor cell lines. It is additive or synergistic in vitro with a range of other antiretrovirals, including the proteinase inhibitor saquinavir, in two- and three-way combinations and is active against zidovudine (ZDV)-resistant virus. It exhibits excellent oral bioavailability, with cerebrospinal fluid (CSF)/plasma penetration. In clinical use, stavudine monotherapy exhibits similar antiretroviral activity to ZDV, and is of proven clinical benefit in ZDV-pre-treated patients. In combination with ddI and/or nelfinavir it results in more substantial and durable responses in immunological and virological markers than reported with either drug alone. Further data on stavudine in combination with other antiretrovirals are now awaited. Comparative trials in ZDV-experienced patients suggest a similar frequenc...Keywords
This publication has 20 references indexed in Scilit:
- Drug Evaluations: Drug Evaluation Anti-infectives: Activity and role of lamivudine in the treatment of adults with human immunodeficiency virus type 1 infection: A reviewExpert Opinion on Investigational Drugs, 1996
- Safety and tolerability of zalcitabine (ddC) in patients with AIDS or advanced AIDS-related complex in the European expanded access programmeInternational Journal of Antimicrobial Agents, 1996
- Lamivudine or Stavudine in Two- and Three-Drug Combinations against Human Immunodeficiency Virus Type 1 Replication In VitroThe Journal of Infectious Diseases, 1996
- Population pharmacokinetics of stavudine (d4T) in patients with AIDS or advanced AIDS-related complexAntimicrobial Agents and Chemotherapy, 1995
- Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicityAIDS, 1994
- Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'-dideoxythymidine in cell cultureAntimicrobial Agents and Chemotherapy, 1994
- The ex vivo Transfer of the Anti-HIV Nucleoside Compound d4T in the Human PlacentaGynecologic and Obstetric Investigation, 1994
- Identification of the nucleotide binding site of HIV-1 reverse transcriptase using dTTP as a photoaffinity labelBiochemistry, 1993
- Zidovudine induces molecular, biochemical, and ultrastructural changes in rat skeletal muscle mitochondria.Journal of Clinical Investigation, 1992
- Comparative Studies of 2′,3′‐Didehydro‐2′,3′‐Dideoxythymidine (D4T) with other Pyrimidine Nucleoside AnaloguesAnnals of the New York Academy of Sciences, 1990